Despite the discovery of BCR-ABL in 1960, it was not until 36 years later in 1996, when Imatinib was discovered to be an inhibitor of ABL and used to treat BCR-ABL positive CML [12, 13]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.